Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

152 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2019.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 51,033,735 shares of 104,661,494 outstanding shares and own 49% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5,788,045 shares), ArrowMark Colorado Holdings LLC (4,840,636 shares), JPMORGAN CHASE & CO (4,024,157 shares), BlackRock Inc. (3,688,657 shares), FRANKLIN RESOURCES INC (3,582,972 shares), Essex Woodlands Management, Inc. (3,342,047 shares), VANGUARD GROUP INC (2,530,046 shares), Capital World Investors (2,130,000 shares), ALLIANCEBERNSTEIN L.P. (1,950,975 shares), and NovaQuest Capital Management, L.L.C. (1,558,426 shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.